Iambic Therapeutics vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 55)
Iambic Therapeutics logo

Iambic Therapeutics

ChallengerHealthcare Tech

AI Drug Discovery

AI drug discovery biotech with $1.7B Takeda deal (Feb 2026). Lead drug IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1. $100M+ raised (2025). Founded 2019, San Diego.

AI VisibilityBeta
Overall Score
C55
Category Rank
#167 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
57
Gemini
51

About

Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company built proprietary machine learning models for structure-based drug design, training its systems on large datasets of protein-ligand interactions to accelerate hit identification, lead optimization, and candidate selection. This computational-first approach compresses timelines that traditionally require years of iterative chemistry work into months.\n\nIambic's lead asset, IAM1363, is a brain-penetrant HER2 inhibitor targeting HER2-mutated cancers including non-small cell lung cancer and breast cancer with brain metastases — a patient population with limited treatment options and high unmet need. The candidate entered Phase 1 clinical trials as a direct output of Iambic's AI design pipeline, validating the platform's ability to produce clinically viable molecules. The company's AI models are designed to simultaneously optimize for potency, selectivity, and the blood-brain barrier permeability that makes IAM1363 differentiated from approved HER2 inhibitors.\n\nIambic secured a $1.7B collaboration deal with Takeda in February 2026, one of the largest AI drug discovery partnerships in the industry's history, validating both the platform and its pipeline at the highest commercial level. The company raised over $100M in 2025 and has positioned itself alongside Recursion and Insilico Medicine as a leading AI-first biotech with clinical-stage proof points. The Takeda deal provides non-dilutive capital and development resources while preserving Iambic's pipeline optionality across multiple oncology indications.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

55
Overall Score
80
#167
Category Rank
#18
79
AI Consensus
83
stable
Trend
stable
59
ChatGPT
78
57
Perplexity
78
51
Gemini
80
60
Claude
84
56
Grok
77

Key Details

Category
AI Drug Discovery
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Iambic Therapeutics
AI Drug Discovery

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.